|
|
Halozyme Therapeutics, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: HALO Results Helen needs to stop sitting on her laurels and acquires a platform as Enhanze subcutaneous patent expires in 2027. Actinium Pharmaceuticals ATNM would be a perfect fit. The joint platforms would create patentable co-formulations through 2030. |
||||||||||||
|
|
return to message board, top of board |
